Balyasny Asset Management’s Genmab GMAB Stock Holding History

Balyasny Asset Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.88M	Buy	+141,100	New	+$3.75M	﹤0.01%	1489

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Balyasny Asset Management's GMAB Position: Q1 2026 in Review

Balyasny Asset Management sold out of Genmab (GMAB) in Q1 2026, closing a stake of 379,364 shares — an estimated $11.7M sold.

Balyasny Asset Management first reported a position in GMAB in Q4 2019 and held it in 9 quarters. The position peaked at $11.7M in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Balyasny Asset Management reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 379,364 Genmab shares in Q1 2026, an estimated $11.7M.
Balyasny Asset Management first reported a position in Genmab in Q4 2019 and held it in 9 quarters.
Balyasny Asset Management's Genmab position peaked at $11.7M in Q4 2025.
275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.